Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab plus radiotherapy versus radiotherapy for glucocorticoid-insensitive active thyroid-associated ophthalmopathy
ChiCTR2100046400Phase 4Recruiting
- Sponsor
- Shanghai Ninth People's Hospital
- Start
- Apr 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of rituximab in Graves Orbitopathy (GO) (2 arms), sponsored by Shanghai Ninth People's Hospital. Primary endpoints: Change in eyeball proptosis, Change in clinical activity score and 3 more. Started Apr 2021; status: recruiting.
02
Drugs
rituximab
03
Conditions
Graves Orbitopathy (GO)
Beyond the preview
Go deeper on ChiCTR2100046400.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100046400.